PREPARATION AND CHARACTERIZATION OF 5-FLUOROURACIL-LOADED MICROPARTICLES AS BIODEGRADABLE ANTICANCER DRUG CARRIERS

被引:85
作者
BOISDRONCELLE, M
MENEI, P
BENOIT, JP
机构
[1] FAC PHARM ANGERS,PHARM GALEN & BIOPHYS PHARMACEUT LAB,F-49100 ANGERS,FRANCE
[2] CHU ANGERS,SERV NEUROCHIRURG,F-49033 ANGERS 01,FRANCE
关键词
D O I
10.1111/j.2042-7158.1995.tb05760.x
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
To provide a device releasing 5-fluorouracil in a controlled manner and injectable into the brain by stereotaxy, biodegradable poly ((+/-)-lactide-co-glycolide) (PLAGA) microparticles were prepared by an emulsion-extraction process. Although the solubility profile of the drug was not suitable for its encapsulation by the aforementioned method, careful choice of process variables allowed significant drug loading, reaching 30%. Thus, the size of the 5-fluorouracil crystals, the organic phase/aqueous phase ratio, the theoretical drug loading and the microparticle size played a predominant role. The microsphere size was adjusted to 20-40 mu m by selecting the appropriate PLAGA and polyvinylalcohol concentrations, and the stirring rate of the initial emulsion. It was shown that the microparticle structure depended directly on the experimental conditions governing the precipitation rate of the coating material: two types of microparticles, I and II, were characterized. The morphology of the particles influenced the 5-fluorouracil-release patterns, as did other process parameters, such as the 5-fluorouracil crystal size and the PLAGA concentration. It was possible to sustain the 5-fluorouracil release over 18 days.
引用
收藏
页码:108 / 114
页数:7
相关论文
共 11 条
[1]
EFFECT OF THE EXTENT OF SURGICAL RESECTION ON SURVIVAL AND QUALITY-OF-LIFE IN PATIENTS WITH SUPRATENTORIAL GLIOBLASTOMAS AND ANAPLASTIC ASTROCYTOMAS [J].
AMMIRATI, M ;
VICK, N ;
LIAO, Y ;
CIRIC, I ;
MIKHAEL, M .
NEUROSURGERY, 1987, 21 (02) :201-206
[2]
FLUOROURACIL, DOXORUBICIN, CISPLATIN AND ALTRETAMINE IN THE TREATMENT OF METASTATIC CARCINOMA OF UNKNOWN PRIMARY [J].
BECOUARN, Y ;
BRUNET, R ;
BARBEGASTON, C .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (05) :861-865
[3]
SOLVENT SELECTION IN THE PREPARATION OF POLY(DL-LACTIDE) MICROSPHERES PREPARED BY THE SOLVENT EVAPORATION METHOD [J].
BODMEIER, R ;
MCGINITY, JW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 43 (1-2) :179-186
[4]
INTERSTITIAL CHEMOTHERAPY WITH DRUG POLYMER IMPLANTS FOR THE TREATMENT OF RECURRENT GLIOMAS [J].
BREM, H ;
MAHALEY, S ;
VICK, NA ;
BLACK, KL ;
SCHOLD, SC ;
BURGER, PC ;
FRIEDMAN, AH ;
CIRIC, IS ;
ELLER, TW ;
COZZENS, JW ;
KENEALY, JN .
JOURNAL OF NEUROSURGERY, 1991, 74 (03) :441-446
[5]
BREM H, 1993, EUR J PHARM BIOPHARM, V39, P2
[6]
DEYME M, 1992, J BIOACT COMPAT POLY, V7, P150
[7]
CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL [J].
DIASIO, RB ;
HARRIS, BE .
CLINICAL PHARMACOKINETICS, 1989, 16 (04) :215-237
[8]
BIODEGRADATION AND BRAIN-TISSUE REACTION TO POLY(D,L-LACTIDE-CO-GLYCOLIDE) MICROSPHERES [J].
MENEI, P ;
DANIEL, V ;
MONTEROMENEI, C ;
BROUILLARD, M ;
POUPLARDBARTHELAIX, A ;
BENOIT, JP .
BIOMATERIALS, 1993, 14 (06) :470-478
[9]
NEUWELT EA, 1983, CANCER RES, V43, P5278
[10]
BIODEGRADABLE CISPLATIN MICROSPHERES PREPARED BY THE SOLVENT EVAPORATION METHOD - MORPHOLOGY AND RELEASE CHARACTERISTICS [J].
SPENLEHAUER, G ;
VERT, M ;
BENOIT, JP ;
CHABOT, F ;
VEILLARD, M .
JOURNAL OF CONTROLLED RELEASE, 1988, 7 (03) :217-229